The Italian Network for Tumor Biotherapy (NIBIT). Sharing visions, goals and efforts at European level

Michele Maio1,2, Ester Fonsatti1, Arianna Burigo1, and Giorgio Parmiani3

1Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena; 2Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano (PN); 3Unit of Immuno-Biotherapy of Solid Tumors, San Raffaele Scientific Institute, Milan, Italy

ABSTRACT

In the context of the Scientific Week 2008 of the Organisation of the European Cancer Institutes, the Italian Network for Tumor Biotherapy (NIBIT), within its initiatives sponsored by Alleanza Contro il Cancro, the Italian Network of Comprehensive Cancer Centers has contributed to organize the Workshop of the European Networks for bio-immunotherapy of tumors. Representatives from the Nordic Center of Excellence for the Development of Anti-Tumor Vaccines (Sweden), the German Network of Immunotherapy of Tumors (Germany), the Biotherapy Development Association and NIBIT gathered to present their organization and ongoing scientific activities, as well as to identify common strategies and shared efforts to push the field of cancer bio-immunotherapy forward at a European level. This article briefly summarizes the history and objectives of NIBIT, along with the actions so far taken by the Network.

Key words: biotherapy, cancer, immunotherapy, networks.

Acknowledgments: This work was supported in part by a grant from Alleanza Contro il Cancro (MM and GP).

Correspondence to: Michele Maio, Division of Medical Oncology and Immunotherapy, Department of Oncology, Istituto Toscano Tumori, University Hospital of Siena, Strada delle Scotte 14, 53100 Siena, Italy.
Tel +39-0577-586336; fax +39-0577-586303; e-mail mmario@cro.it